Ann K Weber

US Patent:

6699871, Mar 2, 2004

Filed:

Jul 5, 2002

Appl. No.:

10/189603

Inventors:

Scott D. Edmondson - New York NJ
Michael H. Fisher - Ringoes NJ
Dooseop Kim - Westfield NJ
Malcolm Maccoss - Freehold NJ
Emma R. Parmee - Scotch Plains NJ
Ann E. Weber - Scotch Plains NJ
Jinyou Xu - Scotch Plains NJ

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C07D48704

US Classification:

514249, 544350

Abstract:

The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (âDP-IV inhibitorsâ) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

US Patent:

7125873, Oct 24, 2006

Filed:

Jul 5, 2002

Appl. No.:

10/481353

Inventors:

Scott D Edmondson - New York NJ, US
Michael H. Fisher - Ringoes NJ, US
Dooseop Kim - Westfield NJ, US
Malcolm Maccoss - Freehold NJ, US
Emma R. Parmee - Scotch Plains NJ, US
Ann E Weber - Scotch Plains NJ, US
Jinyou Xu - Scotch Plains NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/44

US Classification:

514249, 514183, 514247, 514248, 514277, 514279, 514280

Abstract:

The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

US Patent:

7884104, Feb 8, 2011

Filed:

Sep 27, 2005

Appl. No.:

11/662064

Inventors:

Jason M. Cox - East Windsor NJ, US
Scott D. Edmondson - Clark NJ, US
Bart Harper - New York NJ, US
Ann E. Weber - Scotch Plains NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/4545
C07D 487/04

US Classification:

514250, 514248, 514249, 51425203, 51425505, 514256, 5142593, 5142641, 514275, 514303, 514313, 514318, 544236, 544238, 544279, 544326, 544328, 544350, 544405, 546118, 546159, 546173, 546194

Abstract:

The present invention is directed to novel substituted aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

US Patent:

20120149683, Jun 14, 2012

Filed:

Sep 15, 2010

Appl. No.:

13/390708

Inventors:

Jason M. Cox - East Windsor NJ, US
Tesfaye Biftu - Freehold NJ, US
Hong Dong Chu - Livingston NJ, US
Danqing Feng - Green Brook NJ, US
Ann E. Weber - Scotch Plains NJ, US

International Classification:

A61K 31/454
C07D 401/12
A61K 31/497
C07D 401/06
A61P 3/10
C07D 487/04
A61K 31/4985
C07D 413/06
A61K 31/5377
C07D 211/56
A61K 31/4545

US Classification:

51421021, 546199, 514322, 544405, 51425505, 546194, 514318, 544350, 514249, 544129, 5142342

Abstract:

The present invention is directed to novel substituted aminopiperidines of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-ÏV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

US Patent:

20130217695, Aug 22, 2013

Filed:

Mar 20, 2013

Appl. No.:

13/847646

Inventors:

Michael H. Fisher - Flemington NJ, US
Dooseop Kim - Westfield NJ, US
Malcolm Maccoss - Seabrook Island SC, US
Emma R. Parmee - Doylestown PA, US
Ann E. Weber - Scotch Plains NJ, US
Jinyou Xu - Scotch Plains NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 487/04

US Classification:

514249

Abstract:

The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

US Patent:

55411975, Jul 30, 1996

Filed:

Mar 21, 1995

Appl. No.:

8/404566

Inventors:

Michael H. Fisher - Ringoes NJ
Elizabeth M. Naylor - Scotch Plains NJ
Ann E. Weber - Scotch Plains NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D21504
A61K 3147

US Classification:

514311

Abstract:

Substituted sulfonamides are selective. beta. sub. 3 adrenergic receptor agonists with very little. beta. sub. 1 and. beta. sub. 2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.

US Patent:

55611427, Oct 1, 1996

Filed:

May 22, 1995

Appl. No.:

8/445630

Inventors:

Michael H. Fisher - Ringoes NJ
Elizabeth M. Naylor - Scotch Plains NJ
Dong Ok - Edison NJ
Ann E. Weber - Scotch Plains NJ
Thomas Shih - Edison NJ
Hyun Ok - Edison NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D41312
C07D21330
A61K 3144
A61K 3147

US Classification:

514312

Abstract:

Substituted sulfonamides are selective. beta. sub. 3 adrenergic receptor agonists with very little. beta. sub. 1 and. beta. sub. 2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.

US Patent:

57145067, Feb 3, 1998

Filed:

Sep 23, 1996

Appl. No.:

8/717659

Inventors:

Michael H. Fisher - Ringoes NJ
Hyun O. Ok - Edison NJ
Ann E. Weber - Scotch Plains NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3144
C07D21330

US Classification:

514352

Abstract:

Compounds of formula ##STR1## are selective. beta. sub. 3 adrenergic receptor agonists with very little. beta. sub. 1 and. beta. sub. 2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents.